1,588 results on '"Patti, F"'
Search Results
152. Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis
153. Diversity of reproductive features in some Antarctic polynoid and sabellid polychaetes, with a description of Demonax polarsterni sp. n. (Polychaeta, Sabellidae)
154. Frequency and severity of headache is worsened by Interferon-β therapy in patients with multiple sclerosis
155. Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica
156. Clinical features of Sjogren’s syndrome in patients with multiple sclerosis
157. Botulinum toxin improves dysphagia associated with multiple sclerosis
158. The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis
159. Italian multiple sclerosis register as the basis for post-authorization safety studies
160. Box and block test, hand grip strength and nine‐hole peg test: correlations between three upper limb objective measures in multiple sclerosis
161. Efficacy of levetiracetam on upper limb movement in multiple sclerosis patients with cerebellar signs: a multicenter double‐blind, placebo‐controlled, crossover study
162. Position Locking/Channelling Optomechanically Gain-Assisted of Plasmonic/Dielectric Nanoshells in a Optical Tweezers
163. Stroke incidence and survival in three Sicilian municipalities
164. Prevalence of dysphagia in a consecutive cohort of subjects with MS using fibre-optic endoscopy
165. PND28 THE ECONOMIC BURDEN OF MULTIPLE SCLEROSIS DEVELOPMENT OVER TIME: AN ANALYSIS FROM THE MULTIPLE SCLEROSIS CENTERS PERSPECTIVE
166. Efficacy of satralizumab in subgroups of patients in SAkuraSky: A phase III double-blind, placebo-controlled, add-on study in patients with neuromyelitis optica spectrum disorder (NMOSD)
167. Variable effects of cyclophosphamide in rodent models of experimental allergic encephalomyelitis
168. Identifying neuropathic pain in patients with multiple sclerosis: a cross-sectional multicenter study using highly specific criteria
169. An exploration of anger phenomenology in multiple sclerosis
170. Dimensions of care model and pediatric audiology
171. Failed newborn hearing screens as presentation for otitis media with effusion in the newborn population
172. International Space Station Air Quality Assessed According to Toxicologically-Grouped Compounds
173. Headache and multiple sclerosis: a population-based case–control study in Catania, Sicily
174. Management of swallowing disorders in multiple sclerosis
175. Diauxie and co-utilization are not exclusive during growth in nutritionally complex environments
176. Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis
177. Therapeutic lag in relapsing multiple sclerosis
178. Comparison of the effectiveness of rituximab versus alemtuzumab and natalizumab in active relapsing-remitting MS
179. Real-world experience with Ocrelizumab in the MSBase Registry
180. Correction to: The Italian multiple sclerosis register (Neurological Sciences, (2019), 40, 1, (155-165), 10.1007/s10072-018-3610-0)
181. Digital Inheritance and Post Mortem Data Protection: The Italian Reform
182. Real-world experience with Ocrelizumab in the MSBase Registry
183. Introducing Machine Learning for full MS patient trajectories improves predictions for disability score progression
184. Effectiveness of Natalizumab on Multiple Sclerosis patients: the Italian registry experience
185. Prevalence of epilepsy. A door-to-door survey in the sicilian community of riposto
186. Disorders of micturition in neurological patients; A clinical study of 786 patients
187. Reliability of death certificates in the study of stroke mortality. A retrospective study in a Sicilian municipality
188. Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study
189. A double blind, placebo-controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN
190. Tracking a mass mortality outbreak of pen shell Pinna nobilis populations: A collaborative effort of scientists and citizens
191. Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod
192. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity
193. Temporal variations of iodine-127, potassium-40 and technetium-99 concentrations in Fucus serratus in the English Channel
194. Quality of life, depression and fatigue in mildly disabled patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study
195. Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach
196. Erratum to 'Choices of Stent and Cerebral Protection in the Ongoing ACST-2 Trial: A Descriptive Study' (European Journal of Vascular and Endovascular Surgery (2017) 53(5) (617–625) (S1078588417300424) (10.1016/j.ejvs.2016.12.034))
197. Erratum to âChoices of Stent and Cerebral Protection in the Ongoing ACST-2 Trial: A Descriptive Studyâ (European Journal of Vascular and Endovascular Surgery (2017) 53(5) (617â625) (S1078588417300424) (10.1016/j.ejvs.2016.12.034))
198. Vanishing Ann Arbor
199. Combination of cyclophosphamide and interferon-β halts progression in patients with rapidly transitional multiple sclerosis
200. Natural interferon-β treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients. A two-year study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.